Denise L. Faustman is currently Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. Dr. Faustman has worked in the field of autoimmunity for over 15 years and has made some of the key discoveries regarding the role of MHC Class I antigen presentation in immunity. Her earlier research achievements include introducing the concept of modifying antigens on donor tissues to prevent their rejection, a scientific accomplishment that is now in human clinical trials for diverse human diseases treatable with cellular transplants. In 2001, her lab reversed type 1 diabetes in mice with end stage disease, a project that is now being translated into human clinical trials. Her current research continues to focus on uncovering new treatments for type 1 diabetes, as well as searching for therapies for other autoimmune diseases, including Crohn’s disease, lupus, scleroderma, rheumatoid arthritis, Sjogren’s syndrome, and multiple sclerosis After completing her internship, residency, and fellowships in Internal Medicine and Endocrinology at the MGH, Dr. Faustman became an independent investigator at the MGH and Harvard Medical School in 1987. She is a member of the American Association for the Advancement of Science (AAAS) and has served on several NRC and IOM committees including the NRC Standing Committee on Biodefense for the U.S. Department of Defense. In 2003, Dr. Faustman was honored by National Institutes of Health and the National Library of Medicine, with the “Changing the Face of Medicine” award. She was one of 300 American physicians honored for achievement in medicine, past and present. In 2005, she received the Oprah Achievement Award, Top Health Breakthrough by a Female Scientist. In 2006, she was awarded the Women in Science Award, American Medical Women’s Association and Wyeth Pharmaceutical Company given to a female physician who has made exceptional contributions to medical science through basic science publications and through leadership in the field.
No comments:
Post a Comment